Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

Australia

 

WHO warnings of AI in healthcare

In a report published this week by the UN agency, the WHO has raised concerns about the patient safety and potential risks associated with the use of AI language platforms simulating human interactions in healthcare. Public health experts are also calling for a pause on developments until regulations have caught up.

Mubadala-backed M42 buying Diaverum “for $2bn+”

Swedish multinational dialysis firm Diaverum is being bought by M42, a joint venture between Abu Dhabi sovereign wealth fund Mubadala Investment Co and AI firm G42, for a reported $2bn-$2.5bn. Diaverum’s CEO tells HBI the deal offers further opportunities to develop its digital strategies, and international expansion. 

KKR-Ramsay deal looks to be off (again)

The seemingly ill-fated takeover of Australia-based international hospital group Ramsay seems to fallen apart after the consortium led by PE firm KKR refused to amend its second offer which Ramsay called “meaningfully inferior”.

Is Uber Health über or unter?

Uber Health, essentially a taxi service to help non-urgent patients get to hospital appointments, has launched in Australia. But how much will it change healthcare services?

Ramsay rejects new KKR bid after poor results

The acquisition of multinational Australian hospital giant Ramsay Health Care by a consortium led by US PE firm KKR looks likely to fall through, as KKR lowered its offer almost immediately after Ramsay reported disappointing FY2022 results and Ramsay then rejected the new offer.

Bupa and Ramsay Australia resolve tariff tiff

Insurer Bupa and the Australian branch of multinational hospital chain Ramsay have managed to reach an in-principle agreement over price increases, ensuring Bupa-insured Australians will be able to continue to receive care in Ramsay hospitals for the next three years.

Ramsay deal at risk due to French connection

The US$15bn KKR acquisition of Australia-based Ramsay may not go ahead, owing to consistent problems with the hospital group’s French subsidiary. HBI chats to an Australian analyst to find out more.

Find Us